Clinical Trial

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Study acronym: ACS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.
Protocol Amendment History 4 changes
notable Trial sites expanded: 63 -> 68 locations 2026-08-13
notable Trial sites expanded: 60 -> 63 locations 2026-06-24
notable Trial sites expanded: 52 -> 58 locations 2026-04-28
notable Trial sites expanded: 26 -> 52 locations 2026-04-02
Trial Details
NCT Number NCT07102628
Lead Sponsor Novartis Pharmaceuticals
Conditions Acute Coronary Syndrome
Enrollment 300 participants
Start Date 2025-10-03
Primary Completion 2027-02-11 (estimated)
Study Completion 2027-02-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-12